A balanced translocation disrupting BCL2L10 and PNLDC1 segregates with affective psychosis by Bouwkamp, C.G. (Christian G.) et al.
RESEARCH ARTICLENeuropsychiatric GeneticsA Balanced Translocation Disrupting BCL2L10 and
PNLDC1 Segregates With Affective Psychosis
Christian G. Bouwkamp,1,2 Anneke J. A. Kievit,2 Simone Olgiati,2 Guido J. Breedveld,2
Michiel Coesmans,1 Vincenzo Bonifati,2 and Steven A. Kushner1*
1Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands
2Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The NetherlandsManuscript Received: 26 February 2016; Manuscript Accepted: 20 May 2016How to Cite this Article:
Bouwkamp CG, Kievit AJA, Olgiati S,
Breedveld GJ, Coesmans M, Bonifati V,
Kushner SA. 2017. A Balanced
Translocation Disrupting BCL2L10 and
PNLDC1 Segregates With Affective
Psychosis.
Am J Med Genet Part B 174B:214–219.Affective psychoses are a group of severe psychiatric disorders,
including schizoaffective disorder and bipolar I disorder,
together affecting 1% of the population. Despite their high
heritability, themolecular genetics and neurobiology of affective
psychosis remain largely elusive. Here, we describe the identifi-
cation of a structural genetic variant segregating with affective
psychosis in a family with multiple members suffering from
bipolar I disorder or schizoaffective disorder, bipolar type. A
balanced translocation involving chromosomes 6 and 15 was
detected by karyotyping and fluorescence in-situ hybridization
(FISH). Using whole-genome sequencing, we rapidly delineated
the translocation breakpoints as corresponding intragenic
events disrupting BCL2L10 and PNLDC1. These data warrant
further consideration for BCL2L10 and PNLDC1 as novel can-
didates for affective psychosis.  2016 The Authors.American Journal of
Medical Genetics Part B: Neuropsychiatric Genetics Published by Wiley Period-
icals, Inc.
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Affective psychoses comprise a group of severely debilitating
psychiatric disorders, including bipolar I disorder and schizoaf-
fective disorder, together affecting 1% of the population [Per€al€a
et al., 2007]. These disorders profoundly impact quality of life,
including education, employment, and interpersonal relationships
[Saarni et al., 2010]. The suicide rate in patients with bipolar
disorder is 16% [Clements et al., 2013].
Bipolar disorder is well known to have a strong genetic
component, with heritability estimates as high as 0.75 [Sullivan
et al., 2012]. Despite this, the molecular genetic architecture of
bipolar disorder remains largely unknown. There has been
longstanding interest in the Mendelian genetics of severe mental
illness using family-based linkage approaches [Baron, 2002;
Badner et al., 2013] and genome-wide association studies
(GWAS) [Psychiatric GWAS Consortium Bipolar Disorder
Working Group, 2011]. However, replication of linkage findings2016 The Authors. American Journal of Medical Genetics Part B: Nin independent cohorts has generally been lacking [Lewis et al.,
2003].
The emergence of next-generation sequencing (NGS), such as
whole-exome sequencing and whole-genome sequencing, have
enabled powerful family-based approaches for the identification
of the genetic causes of disease. Here, we report the results of our
investigations in a family with affective psychosis. Using traditional
cytogenetic techniques followed by whole-genome sequencing, we
identified a balanced translocation between the long arms of
chromosomes 6 and 15, which disrupts the genes BCL2L10 and
PNLDC1, and segregates with affective psychosis.europsychiatric Genetics Published by Wiley Periodicals, Inc. 214
FIG. 1. Pedigree. The index patient (III-4) is indicated with an arrow as the proband (P). Shaded symbols indicate family members with affective
psychosis. Subjects from whom DNA was available are numbered. Plus (þ) or minus () symbols indicate the presence or absence of the
balanced translocation.
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Participants
We ascertained a Dutch family of Caucasian ethnicity with a high
incidence of affective psychosis (bipolar I disorder and schizoaf-
fective disorder, bipolar type), compatible with an autosomal
dominant pattern of disease inheritance (Fig. 1). The participants
were diagnosed using the structured interview for DSM-IV
disorders (SCID-1). This study was performed in compliance
with the Declaration of Helsinki and was approved by the medi-
cal-ethical committee of the Erasmus University Medical Center.
All participants provided written informed consent.Cytogenetic Studies
Karyotyping was performed on metaphase chromosomes isolated
from freshly cultured peripheral blood lymphocytes from the index
patient (III-4). Fluorescence in-situ hybridization (FISH) analyses
were performed for the index patient (III-4) on metaphase chromo-
somes derived from freshly cultured peripheral blood lymphocytes
according to previously published methods [Pinkel et al., 1986].
Whole-chromosome-specific paints were obtained from a commer-
cialprovider (Eurodiagnostica,Malmo,Sweden).Probeswere labeled
with either biotin (Bio) or digoxigenin (Dig) using the Nick Labeling
Kit (Roche, Basel, Switserland). Bio/Dig were detected with a one-
layer amplification step using streptavidin Alexa 594 (Molecular
Probes, Eugene, OR) and anti-Dig-fluorescence (Roche). Chromo-
somes were counterstained with Vectashield (Vector, Laboratories,
Burlingame, CA) containing 4,6-diamidino-2-phenylindole (Sigma,
St. Louis, MO). Images were captured using a Zeiss Axioskop II
fluorescence microscope and Genetiscan Power Gene System
(Applied Imaging, Grand Rapids, MI).Whole-Genome Sequencing
Genomic DNA was isolated from peripheral blood using standard
protocols. Whole-genome sequencing was performed in the index
patient (III-4) at 40 average coverage depth (Fig. 1) (Complete
Genomics, Mountain View, CA). After an adapter build-in step,
400 base pair genomic fragments underwent circular PCRamplification on DNA nanoballs. Self-assembling nanoarrays
with one nanoball per well were used for combinatorial probe-
anchor ligation (cPALTM) to build in fluorophore-labeled dNTPs.
Reads were aligned to the human reference genome version
GRCh37/hg19. Mapped reads and coverage depth were used to
identify single nucleotide variants (SNVs), small insertions and
deletions (indels), copy number variants (CNVs), structural rear-
rangements, andmobile element insertions [Drmanac et al., 2010].Polymerase Chain Reaction (PCR) and Sanger
Sequencing
The translocation breakpoint and flanking sequence were con-
firmed by Sanger sequencing in the DNA samples of all ascertained
family members (II-1, II-2, III-1, III-2, III-3, and III-4) (Supple-
mentary Methods, Supplementary Table SI).Reference Sequences
The GRCh37/hg19 build was used for annotation of the whole-
genome sequencing data, design of the Sanger sequencing pri-
mers, and Sanger sequence analysis. All variants identified were
annotated according to GenBank reference sequences with
accession numbers for BCL2L10 (NM_020396) and PNLDC1
(NM_173516).RESULTS
The phenotypic profile of all ascertained family members is
provided in Table I. The index patient (III-4) suffered from
schizoaffective disorder, bipolar type with a history of manic-
psychotic episodes, and multiple inpatient psychiatric hospital
admissions. In addition, she experienced a spontaneous termi-
nation of pregnancy at age 30. She was clinically stable on
a maintenance regimen of 375mg/day quetiapine. The index
patient was the youngest of five siblings, with a brother and
three older sisters. Her eldest sister (III-1) was diagnosed with
bipolar I disorder and maintained on 75mg/day quetiapine with
residual depressive symptoms. The second oldest sister (III-2)
suffered from fibromyalgia, chronic fatigue syndrome, and
TABLE I. Clinical Characteristics
Ped ID II-1 II-2 III-1 III-2 III-3 III-4
t(6;15)(q26;q21) translocation
carrier
Yes No No Yes Yes Yes
DSM-IV Diagnosis Bipolar I
disorder
None None Bipolar I
disorder
None Schizoaffective
disorder,
bipolar type
Age at examination Deceased
(at age
69)
83 53 55 50 40
Age of onset depressive episodes Unknown 16 Na 17
Number of depressive episodes >10 3
Age of onset manic-psychotic
episodes
Unknown 44 Na 23
Number of manic-psychotic episodes 3 1
Medication Unknown Metoprolol,
barnidipine,
triamterene,
carbasalate
calcium
Fentanyl
plasters,
clonidine,
estriadol
valerate,
clonazepam
Quetiapine None Quetiapine
Other diagnoses None Hypertension,
essential
thrombocythemia
Fibromyalgia,
chronic fatigue
syndrome,
anxiety
symptoms
None Three
spontaneous
terminations
of pregnancy
Single
spontaneous
termination of
pregnancy
Educational level Primary
school
Primary school Secondary
education
Secondary
education
Higher
professional
education
Higher
professional
education
216 AMERICAN JOURNAL OF MEDICAL GENETICS PART Banxiety symptoms. Their brother had no significant history of
psychiatric symptoms. Her youngest sister (III-3) had multiple
spontaneous abortions in the first trimester of pregnancy in
the setting of clomifene therapy to induce ovulation, but no
significant history of psychiatric symptoms. Their father (II-1)
was deceased but reported by the family as having a diagnosis
of bipolar I disorder with multiple inpatient psychiatric hospi-
talizations. His medical records were unavailable for indepen-
dent review. Their mother (II-2) had no significant psychiatric
history.
Karyotyping and FISH revealed a balanced translocation in the
index patient (III-4). The translocation breakpoints were localized
to cytogenetic bands at 6q26 and 15q21, with a formal karyotype of
46,XX,t(6;15)(q26;q21) (Fig. 2). In order to map the precise
chromosomal breakpoints, we performed whole-genome sequenc-
ing using Complete Genomics technology and confirmed by
Sanger sequencing (Fig. 3). The breakpoint on chromosome 6
was located in intron 11 of Poly(A)-specific ribonuclease (PARN)-
like domain containing 1 (PNLDC1), which is transcribed from the
forward strand t(6;15)(q26;q21)1097þ1227_1097þ1228. The
breakpoint on chromosome 15 was located in intron 1 of the
gene B-cell lymphoma 2 Like 10 (BCL2L10), which is transcribed
from the reverse strand t(6;15)(q26;q21)538þ 1460_538þ 1461.
As a consequence of this balanced translocation, the structure and
expression of a single copy of both PNLDC1 and BCL2L10 were
disrupted and predicted to result in a heterozygous loss of function.The presence or absence of the translocation was evaluated by
Sanger sequencing in all ascertained family members (Fig. 1).
Individuals II-1, III-1, and III-3 were found to carry the t(6;15)
(q26;q21) translocationwith the identical breakpoints and flanking
sequence as the index patient (III-4). In addition to the Sanger
sequencing confirmation, individuals III-1 and III-3 were also
found to carry the translocation by clinical diagnostic karyotyping.
Individual III-1 had two sons, of which the eldest was confirmed by
clinical diagnostic karyotyping to have inherited the translocation.
Neither of the two children of the index patient III-4 were found to
carry the translocation by clinical genetic testing.DISCUSSION
We identified a balanced translocation disrupting PNLDC1 and
BCL2L10 that segregated with affective psychosis within a family
across at least two generations. Independent genetic replicationwill
be required to definitively evaluate the association of PNLDC1 and
BCL2L10 with affective psychosis.
BCL2L10 encodes a 204 amino acid intracellular membrane-
associated BCL2 family protein which is expressed in the brain and
localized to mitochondria [Zhang et al., 2001]. The BCL2L10
protein functions to negatively regulate apoptosis in themitochon-
drial death pathway by preventing cytochrome c release, caspase 3
activation, and mitochondrial membrane potential collapse
[Zhang et al., 2001; Cory and Adams, 2002]. A previous study
FIG. 2. Cytogenetic studies. (A) Complete karyogram from subject III-4 with the inherited balanced translocation: 46,XX,t(6;15)(q26;q21). (B)
Selected karyogram images demonstrating the heterozygous abnormal representation of chromosome 6 (top row) and chromosome 15
(bottom row). (C and D) Fluorescence in-situ hybridization showing the abnormalities in chromosome 6 (C) and chromosome 15 (D) indicated
by the arrows. In (C), probes pertaining to chromosome 6 are labeled in red, and probes pertaining to chromosome 15 are labeled in green. In
(D), probes pertaining to chromosome 15 are labeled in red, and probes pertaining to chromosome 6 are labeled in green. For both (C) and
(D), chromosomes are visualized in blue.
BOUWKAMP ET AL. 217using array-based expression analysis identified alterations of an
apoptosis-related gene set in lithium-responsive patients with
unipolar depression [Lowthert et al., 2012]. Notably, anti-apopto-
tic BCL2 family transcripts, of which BCL2L10 is a member, were
upregulated while pro-apoptotic family members were downregu-
lated in the lithium responsive group. Analogously, the apoptotic
regulatory function of BCL2L10 may also have contributed to the
occurrence of multiple spontaneous abortions in family members
carrying the BCL2L10 disruption, as two different studies have
confirmed high expression levels of this gene in human oocytes for
which abnormal subcellular localization of BCL2L10 was associ-
ated with poor-quality embryos during preimplantation screening
[Guillemin et al., 2009; Yoon et al., 2009; Guerin et al., 2013].However, an important and non-mutually exclusive possibility is
that the spontaneous abortions are a consequence of embryos
inheriting an unbalanced translocation leading to aneuploidy as a
result of meiosis involving the maternal translocation [Tharapel
et al., 1985].
The other gene disrupted by the balanced translocation,
PNLDC1, encodes a 520 amino acid protein containing an RNa-
seH-like domain and RNAse_CAF1 domain. The poly(A)-specific
ribonuclease group of proteins are involved in deadenylation of
mRNA in eurkaryotes, thereby regulating mRNA levels and trans-
lation. However, the function of the nuclease-containing PARN-
like protein PNLDC1 has not been investigated [Virtanen et al.,
2013].
FIG. 3. Chromosomal rearrangement. (A) Schematic view of the balanced translocation involving chromosomes 6 and 15. (B) Electrophero-
grams of the DNA sequence across the translocation breakpoints.
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with affective psychosis in the regions surrounding BCL2L10 or
PNLDC1, nor for common variants to be associated with affective
psychosis, based on the data in the Johns Hopkins Metamoodics
database for genome-wide linkage which comprises 972 families
with bipolar disorder and schizoaffective disorder and GWAS data
of bipolar disorder comprising 7,616 cases and 10,340 controls
[Seifuddin et al., 2012; Pirooznia et al., 2014]. In addition, the
GWAS dataset from the Psychiatric Genomics Consortium of
11,974 cases and 51,792 controls provides no clear evidence of
common alleles in these regions associated with bipolar disorder
[PsychiatricGWASConsortiumBipolarDisorderWorkingGroup,
2011]. Furthermore, genome-wide exome sequencing studies are
not yet publically available for bipolar disorder to examine the
presence of rare exonic variants in these regions.
Although schizophrenia is a form of non-affective psychosis,
multiple CNVs have been identified which increase the risk of
schizophrenia and bipolar disorder [Rodriguez-Murillo et al.,
2012; Green et al., 2016]. Therefore, we examined the data available
from the recently published Sweden Schizophrenia Exome study
which involved whole-exome sequencing of 2,536 patients with
schizophrenia and 2,543 unaffected controls [Purcell et al., 2014].
In BCL2L10, only a single rare coding variant was identified in the
entire cohort (c.467G>A, p.W156, MAF<0.005, nonsynony-
mous), which was found in one patient and no controls. In
PNLDC1, two coding variants were identified: c.13 C>T, p.R5
present in one patient and one control (within transcript
NM_001271862, the effect of this variant is c.77–31 C>T), and
c.244 C>T, p.L82F (NM_001271862: c.277 C>T p.L93F in) pres-
ent in one patient and two controls. This scenario illustrates the
difficulties in conclusively establishing a disease-causing role for
very rare disease-associated variants. Longitudinal follow-up stud-
ies of this family, in addition to continued screening of other
probands and case/control cohorts for rare coding variants in thesegenes, have the potential to provide further clarity regarding the
pathophysiology of affective psychosis.
The study of patients who carry rare cytogenetic abnormalities
has long been an important strategy for the identification of
candidate disease-causing genes, including the first reported can-
didate gene for psychosis (DISC1) [MacIntyre et al., 2003]. Al-
though highly penetrant mutations are rare causes of psychiatric
disorders, their identification have the potential to highlight
molecular pathways that are mechanistically involved in disease
pathogenesis among the wider group of patients who do not carry
high-penetrancemutations. Prominent examples for brain diseases
with an otherwise complex genetic architecture include the iden-
tification of mutations in the gene coding for amyloid precursor
protein (APP) for Alzheimer’s disease [Goate et al., 1991; Kamino
et al., 1992; Tanzi et al., 1992] and the gene encoding alpha-
synuclein (SNCA) in Parkinson’s disease and dementia with
Lewy bodies [Polymeropoulos et al., 1996]. Therefore, we believe
that family-based genetic studies coupled with next-generation
DNA sequencing technologies hold considerable potential to con-
tribute to the understanding of the neurobiological underpinnings
of severe psychiatric illness.ACKNOWLEDGMENTS
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